← Leaderboards
Ian James Amanna
Najit Technologies, Inc.
$8,106,036
Attributed
$15,987,901
Total exposure
8
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.5M · FY2008–25$2.5M$1.9M$1.3M$625K$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$15,763,730 · 7
CDC$224,171 · 1
By mechanism
R44$9,212,812 · 2
U44$5,372,018 · 2
R43$809,373 · 2
R41$593,698 · 2
Top collaborators
- Mark K Slifka19 shared
- Hong M Moulton1 shared
Others in their field
Top investigators on “Technology”
- David Heimbrook · Leidos Biomedical Research, Inc.$995,338,451
- Sonia M Thomas · Research Triangle Institute$700,865,642
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Eric S Lander · Whitehead Institute For Biomedical Res$606,570,095
- Tracy L Nolen · Research Triangle Institute$474,487,152
- Richard K. Wilson · Washington University$441,856,657
Research focus
TechnologyVirusAttenuatedElderlyVaccinesHydrogen PeroxideImmunogenicityImmunogenicProtective EfficacyVulnerable PopulationsInfantBaseVaccinationVaccine CandidateDoseAdultCessation Of LifePhase I Clinical TrialsYellow Fever VirusReportingSafetyYellow FeverResearch PersonnelAttenuated Vaccines
Grant awards (21)
A Randomized Phase I Clinical Trial of HydroVax-CHIKV, a Novel Inactivated Chikungunya Virus Vaccine$980,963
U44 · FY2025 · AI · contact PI
A Randomized Phase I Clinical Trial of HydroVax-CHIKV, a Novel Inactivated Chikungunya Virus Vaccine$986,133
U44 · FY2024 · AI · contact PI
A Randomized Phase I Clinical Trial of HydroVax-YFV, a Novel Inativated Yellow Fever Vaccine$825,048
U44 · FY2023 · AI · contact PI
A Randomized Phase I Clinical Trial of HydroVax-YFV, a Novel Inativated Yellow Fever Vaccine$997,662
U44 · FY2022 · AI · contact PI
Development of an improved intranasal vaccine against influenza$275,107
R41 · FY2022 · AI · contact PI
A Randomized Phase I Clinical Trial of HydroVax-YFV, a Novel Inativated Yellow Fever Vaccine$999,652
U44 · FY2021 · AI · contact PI
Development of a Yellow Fever Vaccine for a Vulnerable Population$997,494
R44 · FY2020 · AI · contact PI
A Randomized Phase I Clinical Trial of HydroVax-CHIKV, a Novel Inactivated Chikungunya Virus Vaccine$290,420
U44 · FY2020 · AI · contact PI
Development of a Yellow Fever Vaccine for a Vulnerable Population$996,895
R44 · FY2019 · AI · contact PI
Development of an H2O2-inactivated chikungunya virus vaccine$989,109
R44 · FY2019 · AI · contact PI
A Randomized Phase I Clinical Trial of HydroVax-YFV, a Novel Inativated Yellow Fever Vaccine$292,140
U44 · FY2019 · AI · contact PI
Development of a Yellow Fever Vaccine for a Vulnerable Population$1,248,114
R44 · FY2018 · AI · contact PI
Development of an H2O2-inactivated chikungunya virus vaccine$994,841
R44 · FY2018 · AI · contact PI
Optimization of vaccine antigen for the development of improved influenza$224,171
R43 · FY2018 · IP · contact PI
Development of an H2O2-inactivated chikungunya virus vaccine$999,652
R44 · FY2017 · AI · contact PI
Development of a novel platform to enhance intracellular bioavailability of antisense morpholino oligomers$318,591
R41 · FY2016 · AI · contact PI
Development of a Yellow Fever Vaccine for Vulnerable Population$994,154
R44 · FY2013 · AI · contact PI
Development of a Yellow Fever Vaccine for Vulnerable Population$992,669
R44 · FY2012 · AI · contact PI
Development of a Yellow Fever Vaccine for Vulnerable Population$999,884
R44 · FY2011 · AI · contact PI
Development of a Yellow Fever Vaccine for Vulnerable Populations$292,261
R43 · FY2009 · AI · contact PI
Development of a Yellow Fever Vaccine for Vulnerable Populations$292,941
R43 · FY2008 · AI · contact PI